Bronchomycn SIGNED
First in class epithelial Barrier-enhancing medicine for respiratory diseases
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Bronchomycn project word cloud
Explore the words cloud of the Bronchomycn project. It provides you a very rough idea of what is the project "Bronchomycn" about.
Project "Bronchomycn" data sheet
The following table provides information about the project.
| Coordinator |
EPI-ENDO PHARMACEUTICALS EHF
Organization address contact info |
| Coordinator Country | Iceland [IS] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | /SME-1 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-02-01 to 2017-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | EPI-ENDO PHARMACEUTICALS EHF | IS (REYKJAVIK) | coordinator | 50˙000.00 |
Mappa
Project objective
Chronic obstructive pulmonary disease (COPD) is a respiratory disorder that presents airway epithelial barrier failure (EBF) for which there are no efficient drugs, being a leading cause of chronic morbidity.
According to the World Health Organization 64 million people suffered COPD in 2004. The EU-28 and USA accounted for 23 and 12.7 million people respectively, which caused near 200,000 deaths. As a consequence of the medical complications of COPD the economic burden has been estimated as € 48.4 and € 29.3 billion in EU-28 and USA respectively
EpiEndo, aims at commercializing a new drug which will be able to save € 27 billion to EU-28 and USA.
Bronchomycn belong to Barriolides, a new class of compounds that provide effective treatment against EBF. Bronchomycn is structurally based on the well-known azithromycin, but lacks antibiotic activity and it acts by decreasing the permeability of the pulmonary epithelium membrane to toxins and infectious agents.
We have been working since 2014 in collaboration with the Stem Cell Research Unit and the University Hospital and now our product is in the early in-vivo stages, for what we have invested € 0.5 Mill. In order to get Bronchomycn to the market, we will start the Clinical studies in 2018 and we expect that current knowledge about side effects of azithromycin speed up the process so that the product will be ready for commercialization in 2021.
During Phase 1 we will prepare the preclinical studies in rodents and clinical studies and defining end-points and regulatory requirements, prepare IPR protection plan, etc.
The market for Bronchomycn is the respiratory therapeutics market which was valued at € 24.8 billion in 2015. We plan to start our sales in Europe in 2022 and USA in 2024, so that by 2026 our turnover will reach €807 Mill.
Therefore, we have decided to continue with Bronchomycn for what we need an additional investment of € 49 Mill, that considering a 5-years forecast will give us a ROI of 14.2
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRONCHOMYCN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BRONCHOMYCN" are provided by the European Opendata Portal: CORDIS opendata.